# Schedules of Controlled Substances: Diphenidine Schedule I Placement > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/diphenidine-schedule-i-placement-controlled-substances/ > **Published:** 2026-06-10T21:55:29-04:00 | **Last Modified / Clinically Audited:** 2026-09-29T00:23:36-04:00 > **Clinical Summary:** Learn about diphenidine schedule I placement and its impact on controlled substances regulation and clinical practice. --- ✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch  |  Federal Register cannabis_policyfederal_lawDEA_schedulingcontrolled_substancesdiphenidine_schedule_Istate_regulationmarijuana_legislation Clinical Summary The Drug Enforcement Administration has placed diphenidine, a synthetic dissociative compound structurally similar to phencyclidine, into Schedule I of the [Controlled Substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/) Act due to its abuse potential and lack of accepted medical use. This regulatory action reflects ongoing efforts to control novel psychoactive substances that emerge in illicit drug markets, though diphenidine itself has limited direct relevance to cannabis clinical practice. However, the scheduling decision underscores broader regulatory patterns affecting controlled substance oversight and the challenges clinicians face when patients present with use of emerging synthetic drugs that may complicate [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) assessment or [drug interaction](https://cedclinic.com/glp-1-addiction-risk-reduction-benefits/) profiles. For cannabis-prescribing clinicians, awareness of synthetic dissociative scheduling reinforces the importance of comprehensive substance use screening, as patients may combine cannabis with other controlled or uncontrolled novel psychoactive substances. The practical takeaway for clinicians is to remain informed about DEA scheduling updates for novel substances and to screen cannabis patients thoroughly for concurrent use of synthetic drugs that could affect treatment safety and efficacy. Clinical Perspective 🧠 The DEA’s decision to schedule diphenidine as a Schedule I controlled substance reflects ongoing regulatory efforts to address novel dissociative drugs in the illicit market, though clinicians should recognize that diphenidine has limited human safety or efficacy data and was never developed for therapeutic use. This action underscores the challenge regulatory agencies face in keeping pace with emerging synthetic drugs while patients and providers in states with [cannabis legalization](https://cedclinic.com/the-forgotten-history-of-hemp-in-america/) may encounter similar compounds in unregulated products, creating unpredictable exposure risks. Given the structural and pharmacological similarities between diphenidine and other dissociatives like PCP and ketamine, clinicians should maintain clinical suspicion for acute dissociative intoxication or mental health sequelae in patients reporting use of novel or unidentified substances, particularly when standard drug screens are unrevealing. While this scheduling decision removes diphenidine from retail circulation in most jurisdictions, the fundamental issue remains that rapid 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/ask-dr-caplan/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Schedules+of+Controlled+Substances%3A+Placement+of+Diphenidine+in+Schedule+I+%40drcaplan&url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F05%2F26%2F2026-10380%2Fschedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F05%2F26%2F2026-10380%2Fschedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Schedules+of+Controlled+Substances%3A+Placement+of+Diphenidine+in+Schedule+I+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F05%2F26%2F2026-10380%2Fschedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) Related Articles - [FDA Cannabis Products Move from Schedule I to Schedule III Under New DEA Rule](https://cedclinic.com/cannabis-schedule-iii-reclassification-fda-approved-products/) - [DEA Places Four Synthetic Cannabinoids in Schedule I](https://cedclinic.com/dea-schedule-i-synthetic-cannabinoids-control-update/) - [DEA Places Synthetic Cannabinoid CUMYL-PEGACLONE in Schedule I](https://cedclinic.com/cumyl-pegaclone-schedule-i-placement-dea-synthetic-cannabinoid/) 📰 Source: [https://www.federalregister.gov/documents/2026/05/26/2026-10380/schedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i](https://www.federalregister.gov/documents/2026/05/26/2026-10380/schedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Schedules of Controlled Substances: Placement of Diphenidine in Schedule I](https://cedclinic.com/diphenidine-scheduling-update-schedule-i-placement/) Explore detailed regulatory updates on diphenidine’s classification and its implications for [controlled substances policy](https://cedclinic.com/dea-synthetic-opioids-schedule-i-march-17-2026/). [Read More](https://cedclinic.com/diphenidine-scheduling-update-schedule-i-placement/) Schedules of [Controlled Substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/): Placement of Diphenidine in Schedule I Review the DEA’s scheduling decisions and clinical relevance of diphenidine as a synthetic dissociative drug. Learn More [Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I](https://cedclinic.com/synthetic-cannabinoids-schedule-i-designation/) Understand the scheduling of synthetic cannabinoids like CUMYL-PEGACLONE alongside diphenidine for comprehensive substance control. [Explore Now](https://cedclinic.com/synthetic-cannabinoids-schedule-i-designation/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).